Palbociclib: Difference between revisions

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Revision as of 15:20, 12 October 2023 view source Alexander Berchansky (talk \| contribs) 29,637 edits No edit summary ← Older edit		Latest revision as of 11:54, 21 January 2024 view source Michal Harel (talk \| contribs) 31,761 edits No edit summary
Line 1:		Line 1:
	<StructureSection load='' size='340' side='right' caption='~~Caption for this structure~~' scene='10/1001138/Cv/1'>		<StructureSection load='' size='340' side='right' caption='Palbociclib' scene='10/1001138/Cv/1'>
	Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref>		Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. See also [https://en.wikipedia.org/wiki/Palbociclib Palbociclib]. It is a selective inhibitor of the [[cyclin-dependent kinases]] CDK4 and CDK6 (see also [[CDK4]]).<ref name="a2">PMID:19874578</ref><ref name="a3">PMID:24369047</ref>